Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02332902
Title Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
Acronym DCLNF1
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors The University of Texas Health Science Center, Houston
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.